SSTR2 and pituitary gland adenoma: Four ongoing clinical trials are currently evaluating [68Ga]Ga-DOTATOC and [68Ga]Ga-DOTATATE in patients with meningiomas [82,83], pituitary adenomas [80], and other SSTR2-positive brain tumors [81].